Drug Trial Radar · NCT05480436
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,200
Planned (sponsor's estimate)
Start
Aug 5, 2022
Primary completion
Jan 30, 2023
Study completion Jul 30, 2023
Sponsor
- Lead sponsor
- China National Biotec Group Company LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Hunan Provincial Center for Disease Control and Prevention; Sichuan Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention; Xiangya Hospital of Central South University; Beijing Institute of Biological Products Co Ltd.; Chengdu Institute of Biological Products Co.,Ltd.; Shanghai Institute Of Biological Products
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.
Conditions
- Hemolysis
- COVID-19
Interventions
coadministrationBiological
the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
COVID-19 vaccineBiological
received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
IIV4+PPV23Biological
received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
- Seroconversion rate against IIV4Time frame: 28 days after vaccination (Day 28)
- Seroconversion rate against PPV23Time frame: 28 days after vaccination (Day 56)
- Neutralizing antibody GMT against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
- Hemmagglution inhibition antibody GMT against IIV4Time frame: 28 days after vaccination (Day 28)
- IgG antibody GMC against PPV23Time frame: 28 days after vaccination (Day 56)
- Neutralizing antibody geometric mean increase (GMI) against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
- Hemmagglution inhibition antibody GMI against IIV4Time frame: 28 days after vaccination (Day 28)
- IgG antibody GMI against PPV23Time frame: 28 days after vaccination (Day 56)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital Central South University
Changsha, China · Not yet recruiting
Sichuan Center for Disease Control and Prevention
Chengdu, China · Recruiting
Guizhou Center for Disease Control and Prevention
Guiyang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.